Most People Mount a Strong Antibody Response to SARS-CoV-2 That Does Not Decline Rapidly.

[2greys]

The vast majority of individuals infected with mild-to-moderate COVID 19 mount a robust antibody response that is relatively stable for at least five months, according to research conducted at the Icahn School of Medicine at Mount Sinai and published October 28, in the journal Science. Additionally, the research team found that this antibody response correlates with the body’s ability to neutralize (kill) SARS-CoV-2, the virus that causes COVID-19.

“While some reports have come out saying antibodies to this virus go away quickly, we have found just the opposite – that more than 90 percent of people who were mildly or moderately ill produce an antibody response strong enough to neutralize the virus, and the response is maintained for many months,” said Florian Krammer, PhD, Professor of Vaccinology at the Icahn School of Medicine at Mount Sinai and a senior author of the paper. “Uncovering the robustness of the antibody response to SARS-CoV-2, including its longevity and neutralizing effects, is critically important to enabling us to effectively monitor seroprevalence in communities and to determining the duration and levels of antibody that protect us from reinfection. This is essential for effective vaccine development.”

Study findings are based on a dataset of 30,082 individuals, who were screened within the Mount Sinai Health System between March and October, 2020. The antibody test used in this research—an enzyme-linked immunosorbent assay (ELISA)—is based on the virus’s telltale spike protein that contains the machinery that enables it to attach and gain entry into our cells. The ELISA assay was developed, validated, and launched at Mount Sinai by a team of internationally renowned researchers and clinicians. The Mount Sinai antibody test detects the presence or absence of antibodies to SARS-CoV-2 and, importantly, is capable of measuring the titer (level) of antibodies an individual has. The high sensitivity and specificity of this test—meaning that a false negative or false positive is highly unlikely—allowed it to be among the first to receive emergency use authorization from New York State and the U.S. Food and Drug Administration.

mountsinai.org/about/newsro...

Sciencemag. The research paper:

science.sciencemag.org/cont...

[HungryHufflepuff]

So many conflicting and contradictory reports, but hopefully this one is correct.

[Bkin in reply to HungryHufflepuff]

it certainly does depend on what article you read HH and for sure all studies may well be accurate so best to keep an open mind.

In addition we all need to fully understand the information being provided so that we do not confuse information;

-- The above study involved 72K people with mild to moderate symptoms and were being tested for COV-2 antibodies.

The UK study involved 360K from all age groups across England study for Covid 19 antibodies ... stating

" Antibody response over time varies depending on a person’s age and symptoms "

gov.uk/government/news/larg...

There are explanations on you tube about the difference between COV-2 and covid19 ; here is one short video:

youtube.com/watch?v=eqZFUIm...(Not working as expected?)

.

[2greys in reply to Bkin]

It can also depend on which serology tests are used, not all are equally acurate, there is also more than one specific antibody. I tend not to worry too much about antibodies alone. In my view B-cells and T-cells are more important and the consensus is that these are lasting for much a longer term.

[Bkin in reply to 2greys]

I tend to pay more mind to what is happening in UK and how its affecting things here, the main thing being we all need to continue to be extra cautious whatever environment we are living.

B and T cells - everyone's body has them unless they have a really shot immune system where the system is compromised, which is why those already with immune system vulnerability are more at risk with covid19

en.wikipedia.org/wiki/Lymph....

[2greys in reply to Bkin]

Unfortunately, British is not always best nor fastest. The German Pfizer vaccine may be ready before Oxford-AstraZeneca. The AstraZeneca one would be my personal choice because it has shown a robust T-cell response as well as with a wide age range.

pmlive.com/pharma_news/pfiz...